TWI295173B - - Google Patents

Download PDF

Info

Publication number
TWI295173B
TWI295173B TW093106702A TW93106702A TWI295173B TW I295173 B TWI295173 B TW I295173B TW 093106702 A TW093106702 A TW 093106702A TW 93106702 A TW93106702 A TW 93106702A TW I295173 B TWI295173 B TW I295173B
Authority
TW
Taiwan
Prior art keywords
antitumor
effective amount
tegafur
tumor
agent
Prior art date
Application number
TW093106702A
Other languages
English (en)
Chinese (zh)
Other versions
TW200503720A (en
Inventor
Junji Uchida
Koyo Shudo
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TW200503720A publication Critical patent/TW200503720A/zh
Application granted granted Critical
Publication of TWI295173B publication Critical patent/TWI295173B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW093106702A 2003-03-14 2004-03-12 Anti-tumor effect intensifier and antitumor agent TW200503720A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003070097 2003-03-14

Publications (2)

Publication Number Publication Date
TW200503720A TW200503720A (en) 2005-02-01
TWI295173B true TWI295173B (cg-RX-API-DMAC7.html) 2008-04-01

Family

ID=32984641

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093106702A TW200503720A (en) 2003-03-14 2004-03-12 Anti-tumor effect intensifier and antitumor agent

Country Status (21)

Country Link
US (2) US9611227B2 (cg-RX-API-DMAC7.html)
EP (1) EP1604991B1 (cg-RX-API-DMAC7.html)
JP (1) JP4610481B2 (cg-RX-API-DMAC7.html)
KR (1) KR100812693B1 (cg-RX-API-DMAC7.html)
CN (2) CN101357134A (cg-RX-API-DMAC7.html)
AT (1) ATE408408T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004220205B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0408372A (cg-RX-API-DMAC7.html)
CA (1) CA2518195C (cg-RX-API-DMAC7.html)
CY (1) CY1108395T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004016636D1 (cg-RX-API-DMAC7.html)
DK (1) DK1604991T3 (cg-RX-API-DMAC7.html)
ES (1) ES2312978T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05009781A (cg-RX-API-DMAC7.html)
NZ (1) NZ542150A (cg-RX-API-DMAC7.html)
PL (1) PL1604991T3 (cg-RX-API-DMAC7.html)
PT (1) PT1604991E (cg-RX-API-DMAC7.html)
RU (1) RU2334517C2 (cg-RX-API-DMAC7.html)
SI (1) SI1604991T1 (cg-RX-API-DMAC7.html)
TW (1) TW200503720A (cg-RX-API-DMAC7.html)
WO (1) WO2004081012A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106984A1 (ja) * 2005-04-01 2006-10-12 Taiho Pharmaceutical Co., Ltd. ピリジン誘導体を有効成分とする放射線治療増強剤
JP4956423B2 (ja) * 2005-04-01 2012-06-20 大鵬薬品工業株式会社 放射線治療増強剤
JPWO2007043531A1 (ja) * 2005-10-07 2009-04-16 セレスター・レキシコ・サイエンシズ株式会社 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
TW201043237A (en) * 2009-04-22 2010-12-16 Taiho Pharmaceutical Co Ltd Method for predicting a therapeutic effect of the chemotherapy for renal cell cancer
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
WO2012161240A1 (ja) * 2011-05-25 2012-11-29 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
PL3053578T3 (pl) * 2013-09-30 2021-06-14 Taiho Pharmaceutical Co., Ltd. Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69003670T2 (de) 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
EP0500953B1 (en) * 1990-09-07 1996-08-21 Taiho Pharmaceutical Company Limited Antineoplastic effect potentiator and antineoplastic agent
CA2087540C (en) 1991-05-27 1999-01-19 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
AU2001240001A1 (en) * 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
US6770653B2 (en) 2001-03-06 2004-08-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
DE60235088D1 (de) * 2001-07-05 2010-03-04 Taiho Pharmaceutical Co Ltd Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel

Also Published As

Publication number Publication date
JP4610481B2 (ja) 2011-01-12
PL1604991T3 (pl) 2009-02-27
DK1604991T3 (da) 2009-01-05
EP1604991B1 (en) 2008-09-17
CN101357134A (zh) 2009-02-04
US20170157131A1 (en) 2017-06-08
PT1604991E (pt) 2008-10-27
ATE408408T1 (de) 2008-10-15
RU2005131839A (ru) 2006-02-10
CA2518195C (en) 2009-07-07
BRPI0408372A (pt) 2006-03-21
NZ542150A (en) 2009-09-25
MXPA05009781A (es) 2005-10-26
US9814724B2 (en) 2017-11-14
ES2312978T3 (es) 2009-03-01
CA2518195A1 (en) 2004-09-23
SI1604991T1 (sl) 2009-02-28
AU2004220205B2 (en) 2010-06-17
EP1604991A1 (en) 2005-12-14
RU2334517C2 (ru) 2008-09-27
CN1761665A (zh) 2006-04-19
WO2004081012A1 (ja) 2004-09-23
KR20050106119A (ko) 2005-11-08
CY1108395T1 (el) 2014-02-12
KR100812693B1 (ko) 2008-03-13
US20060116345A1 (en) 2006-06-01
DE602004016636D1 (de) 2008-10-30
AU2004220205A1 (en) 2004-09-23
US9611227B2 (en) 2017-04-04
EP1604991A4 (en) 2006-05-03
JPWO2004081012A1 (ja) 2006-06-08
TW200503720A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
JP2011051993A (ja) フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理
JP6462147B2 (ja) Hsp90阻害ペプチド結合体及びその腫瘍治療における応用
KR20220003560A (ko) 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염
WO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
TWI399206B (zh) 抗腫瘤劑
JP2003530353A (ja) オルチプラズの肝繊維化及び肝硬変症進行の予防及び治療剤としての使用方法、及びオルチプラズを主成分として含有する製薬組成物
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
JPWO2017135412A1 (ja) 重度腎機能障害を有する癌患者に対する治療方法
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
US20090281105A1 (en) Radiotherapy enhancer
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JP2024506336A (ja) 膠芽腫の治療方法
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
CN101940569A (zh) 含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
TWI727858B (zh) 維奈托克(venetoclax)之水溶性高分子衍生物
JP5409613B2 (ja) 抗腫瘍剤、キット及び癌治療方法
CN108135894B (zh) 肿瘤治疗剂
KR100844477B1 (ko) 항종양 효과 증강제, 항종양제 및 암 치료 방법
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
CN113181184A (zh) 双氢麦角胺在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent